ATI PN Adult Med Surg 2020 with NGN
ATI PN Adult Med Surg 2020 with NGN ( 101 Questions)
A nurse is collecting data from a client who is taking enoxaparin. The client reports starting the use of dietary supplements. The nurse should report the use of which of the following supplements to the provider?
Echinacea is an herb that is commonly used to boost the immune system and has not been found to interact with enoxaparin.
Flaxseed powder is a dietary supplement that is high in fiber and omega-3 fatty acids and has not been found to interact with enoxaparin.
Probiotics are live bacteria that can be found in certain foods or supplements, and they have not been found to interact with enoxaparin.
Ginkgo biloba is an herb that can interact with enoxaparin and increase the risk of bleeding, so the nurse should report its use to the provider. The other options, A (Echinacea), B (Flaxseed powder), and C (Probiotics) do not have any known interactions with enoxaparin, so they do not need to be reported to the provider.
Reasons why the other choices are not answers are:
Ginkgo biloba is a herb that can interact with enoxaparin and increase the risk of bleeding, so the nurse should report its use to the provider. The other options, A (Echinacea), B (Flaxseed powder), and C (Probiotics) do not have any known interactions with enoxaparin, so they do not need to be reported to the provider.
Reasons, why the other choices are not answers, are:
A. Echinacea is a herb that is commonly used to boost the immune system and has not been found to interact with enoxaparin.
B. Flaxseed powder is a dietary supplement that is high in fiber and omega-3 fatty acids and has not been found to interact with enoxaparin.
C. Probiotics are live bacteria that can be found in certain foods or supplements, and they have not been found to interact with enoxaparin.
In summary, the nurse should report the use of Ginkgo biloba to the provider, as it can interact with enoxaparin and increase the risk of bleeding. Echinacea, Flaxseed powder, and Probiotics do not have any known interactions with enoxaparin, so they do not need to be reported to the provider.